Lhasa Limited shared knowledge shared progress
Loading...

Publications

Jump to results
Authors
Publication Type
Publication Year
Related Products
Reset
New search
TitlePublishedTypeProducts
Product Update ICGM PresentationMarch 2019pdf fileDerek NexusSarah Nexus
Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial settingFebruary 2019Sarah NexusDerek Nexus
Advance your knowledge of ICH M7 A virtual expert review workshopFebruary 2019Derek NexusSarah Nexus
A defined approach for predicting skin sensitisation hazard and potency based on the guided integration of in silico, in chemico and in vitro data using exclusion criteriaJanuary 2019Derek NexusVitic Nexus
Developing an adverse outcome pathway framework for carcinogenicity from alerts in an expert rule-based system.December 2018Derek Nexus
The use of Derek Nexus to facilitate decision-making in chemical safety assessment.December 2018pdf fileDerek Nexus
Save Time and Money with Lhasa LimitedDecember 2018pdf fileDerek NexusSarah NexusZeneth
Welcome and Introduction to ICH M7 - ICH M7 India RoadshowsNovember 2018pdf fileDerek NexusSarah NexusVitic Nexus
Derek Nexus, Sarah Nexus and Vitic: How they fit into ICH M7 - ICH M7 India RoadshowsNovember 2018pdf fileDerek NexusSarah NexusVitic Nexus
Derek Nexus, The Expert System for ICH M7 - ICH M7 India RoadshowsNovember 2018pdf fileDerek Nexus
An adverse outcome pathway framework to support developmental and reproductive toxicity risk assessmentsNovember 2018pdf fileDerek NexusSarah NexusVitic Nexus
A Defined Approach for Predicting Skin Sensitisation Hazard and PotencyNovember 2018pdf fileDerek Nexus
Important considerations for the validation of QSAR models for in vitro mutagenicityNovember 2018Derek NexusSarah NexusVitic Nexus
Improvement of quantitative structure–activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge ProjectOctober 2018Derek NexusSarah Nexus
Extrapolation of in vitro structural alerts for mutagenicity to the in vivo endpointOctober 2018Derek Nexus
In Silico Predictions For GenotoxicityOctober 2018pdf fileDerek NexusSarah Nexus
Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental DataOctober 2018pdf fileDerek NexusVitic Nexus
Meeting report, ICH M7 relevant workshop: use of (Q)SAR systems and expert judgmentSeptember 2018pdf fileDerek NexusSarah Nexus
Development Of A Network Of Adverse Outcome Pathways (AOPs) For CarcinogenicitySeptember 2018pdf fileVitic NexusDerek NexusSarah Nexus
An adverse outcome pathway framework to support the assessment of DART liabilities of compoundsSeptember 2018pdf fileDerek Nexus
Developing an adverse outcome pathway framework for carcinogenicity from alerts in an expert rule-based systemSeptember 2018pdf fileDerek Nexus
A Defined Approach to Skin Sensitisation: Integrating Derek Nexus with In Chemico/In Vitro Assays Based on Exclusion CriteriaAugust 2018pdf fileDerek Nexus
Toxicity Studies for Degradation Impurities - An Industry PerspectiveJune 2018pdf fileDerek NexusSarah Nexus
Improving Toxicity Predictions through knowledge and data sharingJune 2018pdf fileDerek NexusExcipientsIntermediatesiPiEVitic Nexus
ICH M7 Use CasesJune 2018pdf fileDerek NexusSarah Nexus

© 2020 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.